New combo tackles Drug-Resistant lung cancer in early trial
NCT ID NCT06106802
First seen Mar 03, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants will receive daily oral doses of both drugs. The main goal is to see how many patients respond, with secondary aims including how long the benefit lasts and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam-gu, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lazertinib and tepotinib (two oral drugs)
What this could lead to
If successful, this combination could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to initial therapy.
What could go wrong
This is a small, early-phase trial (47 people) with no control group. The benefit may be limited to those with high MET levels, and side effects from the drug combination are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.